Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Takeda Pharma Enters into Agreement with DNDi 11
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 12
Optibrium Enters into Partnership with Imperial College London and DNDi 13
Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 14
Institut Pasteur Korea Enters into Research Agreement with DNDi 15
DNDi Enters into Agreement with Takeda Pharma 16
Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 17
Celgene Global Health Expands Research Agreement DNDi 18
Institut Pasteur Korea and DNDi Enter into Research Agreement 19
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 20
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 21
Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 22
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 23
Drugs for Neglected Diseases initiative – Key Employees 24
Drugs for Neglected Diseases initiative – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Nov 08, 2017: DNDi/GARDP opens new South Africa liaison office, hosted by South African Medical Research Council 27
Corporate Communications 28
Aug 08, 2017: DNDi welcomes Dr Marie-Paule Kieny as new Chair of the Board of Directors with Prof. Marcel Tanner stepping down after ten successful years 28
Government and Public Interest 29
Sep 12, 2018: New hope for PKDL patients in Africa as clinical trial aims to make treatment safer and easier 29
Apr 13, 2018: Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa 30
Feb 06, 2018: New open source drug discovery project aims to develop mycetoma treatment 31
Other Significant Developments 32
Jan 18, 2018: Epichem Awarded One Year Contract Extension from DNDi 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Key Facts 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Drugs for Neglected Diseases initiative, Deals By Therapy Area, 2012 to YTD 2018 8
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Takeda Pharma Enters into Agreement with DNDi 11
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 12
Optibrium Enters into Partnership with Imperial College London and DNDi 13
Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 14
Institut Pasteur Korea Enters into Research Agreement with DNDi 15
DNDi Enters into Agreement with Takeda Pharma 16
Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 17
Celgene Global Health Expands Research Agreement DNDi 18
Institut Pasteur Korea and DNDi Enter into Research Agreement 19
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 20
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 21
Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 22
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 23
Drugs for Neglected Diseases initiative, Key Employees 24
Drugs for Neglected Diseases initiative, Other Locations 26
List of Figures
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8